Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 57Carcinoma, Non-Small-Cell Lung 35Urinary Bladder Neoplasms 32Neoplasm Metastasis 20Lung Neoplasms 19Ovarian Neoplasms 18Lymphoma, Large B-Cell, Diffuse 18Cholangiocarcinoma 15Nasopharyngeal Carcinoma 14Biliary Tract Neoplasms 14Triple Negative Breast Neoplasms 13Neoplasms 13Colorectal Neoplasms 12Breast Neoplasms 12Carcinoma, Transitional Cell 11Non-Muscle Invasive Bladder Neoplasms 10Recurrence 9Fallopian Tube Neoplasms 9Gallbladder Neoplasms 8Sarcoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Bile Duct Neoplasms 6Uterine Cervical Neoplasms 5Osteosarcoma 5Lymphoma, Non-Hodgkin 5Lymphoma 5Hodgkin Disease 5Endometrial Neoplasms 5Melanoma 4Gastrointestinal Neoplasms 4

Interventions

durvalumab 1Gemcitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced or Metastatic Solid Tumours × Gemcitabine × 90 days × Clear all
NCT04999969 2026-04-30

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

AstraZeneca

Phase 2 Active not recruiting
126 enrolled 30 charts
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡